What is the current Cellectis market capitalization?
The current market capitalization of Cellectis is 122.42 M USD.
Cellectis Market capitalization 2024
Cellectis Market capitalization
122.42 M USD
Ticker
ALCLS.PA
ISIN
FR0010425595
WKN
A0MKPR
In 2024, Cellectis's market cap stood at 122.42 M USD, a 12.19% increase from the 109.12 M USD market cap in the previous year.
The Cellectis Market capitalization history
| YEAR | Market Capitalization (undefined USD) |
|---|---|
| 2023 | 0.13 |
| 2022 | 0.16 |
| 2021 | 0.74 |
| 2020 | 0.75 |
| 2019 | 0.66 |
| 2018 | 1.16 |
| 2017 | 0.87 |
| 2016 | 0.86 |
| 2015 | 1.11 |
| 2014 | 0.29 |
| 2013 | 0.14 |
| 2012 | 0.16 |
| 2011 | 0.13 |
| 2010 | 0.13 |
| 2009 | 0.14 |
| 2008 | 0.08 |
| 2007 | 0.15 |
| 2006 | - |
| 2005 | - |
| 2004 | - |
Cellectis Aktienanalyse
What does Cellectis do?
Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Cellectis's Market Capitalization
Cellectis's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Cellectis's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Cellectis's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Cellectis’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Cellectis stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Cellectis.
How has the market capitalization of Cellectis developed in recent years?
The market capitalization of Cellectis has increased/decreased by 12.19% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Cellectis?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Cellectis?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Cellectis have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Cellectis pay?
Over the past 12 months, Cellectis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cellectis is expected to pay a dividend of 0 USD.
What is the dividend yield of Cellectis?
The current dividend yield of Cellectis is .
When does Cellectis pay dividends?
Cellectis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Cellectis?
Cellectis paid dividends every year for the past 0 years.
What is the dividend of Cellectis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Cellectis located?
Cellectis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cellectis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cellectis from 7/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/30/2024.
When did Cellectis pay the last dividend?
The last dividend was paid out on 7/30/2024.
What was the dividend of Cellectis in the year 2023?
In the year 2023, Cellectis distributed 0 USD as dividends.
In which currency does Cellectis pay out the dividend?
The dividends of Cellectis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Cellectis stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Cellectis
Our stock analysis for Cellectis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
